Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
L-697, 661 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| L-697,661 | DRUG | - |
| Zidovudine | DRUG | - |
Inclusion Criteria Patients must have: * HIV infection. Prior Medication: Included: * Patients in Part 1 must have received no previous zidovudine (AZT) or a stable dose of at least 500 mg/day without evidence of toxicity. * Patients in Part 2 must have received no previous AZT or = or \> 300 mg...
Top 18 of 27 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Pfizer Inc. | PFE | 5 | PHASE3 | VLA15, ATM-AVI, PG4, Prevenar 20 |
| Sanofi SA Sponsored ADR | SNY | 2 | PHASE3 | PCV21 |
| Grifols, S.A. Sponsored ADR Class B | GRFS | 1 | PHASE3 | Xembify |
| GSK plc Sponsored ADR | GSK | 3 | PHASE2 | Penmenvy, iNTS-TCV, Strep A vaccine |
| CorMedix Inc. | CRMD | 1 | PHASE3 | DefenCath |
| Sinovac Biotech Ltd. | SVA | 4 | PHASE3 | Sinovac PCV24, Group ACYW135X Meningococcal Conjugate Vaccine, Group ACYW135 Meningococcal Conjugate Vaccine |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE2 | EDI048 |
| Innoviva, Inc. | INVA | 3 | PHASE2 | Eravacycline, Sulbactam-durlobactam |
| BiomX Inc. | PHGE | 1 | PHASE2 | BX004 |
| Merck & Co., Inc. | MRK | 2 | PHASE1 | V118C |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD7760 |
| BioNTech SE Sponsored ADR | BNTX | 1 | PHASE1 | BNT163 |
| 60 Degrees Pharmaceuticals, Inc. | SXTP | 1 | PHASE2 | Tafenoquine |
| Tarsus Pharmaceuticals, Inc. | TARS | 1 | PHASE2 | TP-05 |
| Moderna, Inc. | MRNA | 1 | PHASE2 | mRNA-1982 |
| AN2 Therapeutics, Inc. | ANTX | 1 | PHASE2 | Epetraborole |
| Emergent BioSolutions Inc. | EBS | 4 | - | AIGIV/kg |
| Phathom Pharmaceuticals, Inc. | PHAT | 1 | - | Vonoprazan |
L-697,661 is an investigational small molecule being studied for the treatment of HIV Infections. It is in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being evaluated for its safety and pharmacokinetic profile in patients with HIV.
L-697,661 is being developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The company is conducting clinical research to evaluate the drug's potential in treating HIV Infections.
L-697,661 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved for commercial use. The drug is being studied in early-stage clinical trials to assess its safety, tolerability, and pharmacokinetics in patients with HIV Infections.
L-697,661 has one completed clinical trial registered as NCT00000628, titled "A Pharmacokinetic Study of L-697,661 Alone and in Combination With Zidovudine." This Phase 1 study enrolled 27 participants with HIV Infections in the United States and was not randomized or blinded.
The mechanism of action for L-697,661 has not been disclosed in available clinical trial information. The drug is being studied as a small molecule for HIV Infections, but its specific molecular target has not been publicly specified in the trial data.